Literature DB >> 8605324

gamma-c gene transfer into SCID X1 patients' B-cell lines restores normal high-affinity interleukin-2 receptor expression and function.

H Hacein-Bey1, M Cavazzana-Calvo, F Le Deist, A Dautry-Varsat, C Hivroz, I Rivière, O Danos, J M Heard, K Sugamura, A Fischer, G De Saint Basile.   

Abstract

SCID X1 is characterized by faulty T-cell and natural killer cell differentiation caused by mutation of the gamma-c chain gene encoding a number of multiple cytokine receptors (interleukin-2 [IL-2], IL-4, IL-7, IL-9, and IL-15 receptors). To assess the feasibility of inducing long-term expression and function of the gamma-c chain, Epstein-Barr virus (EBV)-transformed B-cell lines from two patients with SCID X1 were transduced with a Moloney-derived retroviral vector containing the gamma-c chain cDNA. The viral LTR was used as the promoter. Immediately after two cycles of coculture with the psi-crip clone producing the MFG(B2)-gamma-c cDNA vector, gamma-c expression, assessed by detection of the mRNA and membrane protein expression, was found in 15% to 20% of cells. The degree of membrane expression was similar to that in control EBV-B cells. Expression increased steadily over 6 months, becoming detectable in 100% of cells, and remained stable thereafter for a total of 9 months, reflecting positive selection of transduced cells. A study of provirus integration sites showed multiple integration. The expressed gamma-c was functional, because it restored high-affinity IL-2 receptor binding, IL-2 endocytosis, and IL-2-triggered phosphorylation of JAK-3 tyrosine kinase. Similar results were obtained with the two B-cell lines. These results show that efficient gamma-c gene transfer into B-cells lacking functional gamma-c is feasible and results in strong and stable expression of a functional gamma-c chain, apparently conferring a selective growth advantage in culture. Further in vitro studies of gamma-c gene transfer into gamma-c- hematopoietic progenitors are being conducted to assess the feasibility of correcting lymphocyte differentiation defects.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8605324

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

Review 1.  Severe combined immunodeficiencies (SCID).

Authors:  A Fischer
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

Review 2.  Gene therapy of X-linked severe combined immunodeficiency.

Authors:  Salima Hacein-Bey-Abina; Alain Fischer; Marina Cavazzana-Calvo
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

Review 3.  Hematopoietic stem cell engineering at a crossroads.

Authors:  Isabelle Rivière; Cynthia E Dunbar; Michel Sadelain
Journal:  Blood       Date:  2011-11-17       Impact factor: 22.113

Review 4.  Gene therapy of primary immunodeficiencies.

Authors:  F Candotti; R M Blaese
Journal:  Springer Semin Immunopathol       Date:  1998

Review 5.  Severe combined immune deficiencies due to defects of the common gamma chain-JAK3 signaling pathway.

Authors:  F Candotti; J J O'Shea; A Villa
Journal:  Springer Semin Immunopathol       Date:  1998

Review 6.  Advances in the understanding of cytokine signal transduction: the role of Jaks and STATs in immunoregulation and the pathogenesis of immunodeficiency.

Authors:  J J O'Shea; L D Notarangelo; J A Johnston; F Candotti
Journal:  J Clin Immunol       Date:  1997-11       Impact factor: 8.317

Review 7.  Gene therapy for immunodeficiency.

Authors:  F Candotti
Journal:  Curr Allergy Asthma Rep       Date:  2001-09       Impact factor: 4.806

8.  Gene therapy researchers' assessments of risks and perceptions of risk acceptability in clinical trials.

Authors:  Claire T Deakin; Ian E Alexander; Cliff A Hooker; Ian H Kerridge
Journal:  Mol Ther       Date:  2013-01-22       Impact factor: 11.454

Review 9.  Update on gene therapy for immunodeficiencies.

Authors:  Donald B Kohn
Journal:  Clin Immunol       Date:  2010-01-13       Impact factor: 3.969

10.  Serial bone marrow transplantation reveals in vivo expression of the pCLPG retroviral vector.

Authors:  Paula Fratini; Bryan E Strauss
Journal:  Virol J       Date:  2010-01-22       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.